Protection from herpes simplex virus type 1 lethal and latent infections by secreted recombinant glycoprotein B constitutively expressed in human cells with a BK virus episomal vector
- PMID: 2152829
- PMCID: PMC249122
- DOI: 10.1128/JVI.64.1.431-436.1990
Protection from herpes simplex virus type 1 lethal and latent infections by secreted recombinant glycoprotein B constitutively expressed in human cells with a BK virus episomal vector
Abstract
The herpes simplex virus type 1 (HSV-1) glycoprotein B (gB-1) gene, deleted of 639 nucleotides that encode the transmembrane anchor sequence and reconstructed with the extramembrane and intracytoplasmic domains, was cloned under control of the Rous sarcoma virus long terminal repeat in the episomal replicating vector pRP-RSV, which contains the origin of replication and early region of the human papovavirus BK as well as a cDNA for a mutant mouse dihydrofolate reductase that is resistant to methotrexate. gB-1 (0.15 to 0.25 pg per cell per 24 h) was constitutively secreted into the culture medium of pRP-RSV-gBs-transformed human 293 cells. Treatment of transformed cells with methotrexate at high concentrations (0.6 to 6 microM) increased gB-1 production 10- to 100-fold, because of an amplification of the episomal recombinant. Mice immunized with secreted gB-1 produced HSV-1- and HSV-2-neutralizing antibodies and were protected against HSV-1 lethal, latent, and recurrent infections. Constitutive expression of secreted gB-1 in human cells may establish a system to develop diagnostic material and a subunit vaccine for HSV infections.
Similar articles
-
Constitutive expression in human cells of herpes simplex virus type 1 glycoprotein B gene cloned in an episomal eukaryotic vector.Virology. 1988 Nov;167(1):284-8. doi: 10.1016/0042-6822(88)90080-3. Virology. 1988. PMID: 2847417
-
Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.J Virol. 1988 May;62(5):1530-4. doi: 10.1128/JVI.62.5.1530-1534.1988. J Virol. 1988. PMID: 2833606 Free PMC article.
-
Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice.Science. 1985 May 10;228(4700):737-40. doi: 10.1126/science.2986288. Science. 1985. PMID: 2986288
-
Live vaccinia virus recombinants expressing herpes simplex virus genes.Rev Infect Dis. 1991 Nov-Dec;13 Suppl 11:S898-903. doi: 10.1093/clind/13.supplement_11.s898. Rev Infect Dis. 1991. PMID: 1664124 Review.
-
Adenovirus vectors as potential vaccines against herpes simplex virus.Rev Infect Dis. 1991 Nov-Dec;13 Suppl 11:S912-6. doi: 10.1093/clind/13.supplement_11.s912. Rev Infect Dis. 1991. PMID: 1664127 Review.
Cited by
-
Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus.Curr Pharm Des. 2007;13(19):1975-88. doi: 10.2174/138161207781039779. Curr Pharm Des. 2007. PMID: 17627531 Free PMC article. Review.
-
A comparison of T cell responses to glycoprotein B (gB-1) of herpes simplex virus type 1 and its non-glycosylated precursor protein, pgB-1.Clin Exp Immunol. 1991 Oct;86(1):30-6. doi: 10.1111/j.1365-2249.1991.tb05769.x. Clin Exp Immunol. 1991. PMID: 1655317 Free PMC article.
-
A BK virus episomal vector for constitutive high expression of exogenous cDNAs in human cells.Arch Virol. 1995;140(2):335-9. doi: 10.1007/BF01309866. Arch Virol. 1995. PMID: 7710358
-
Characterization and immunogenicity of a candidate subunit vaccine against varicella-zoster virus.Med Microbiol Immunol. 1994 May;183(2):105-17. doi: 10.1007/BF00277161. Med Microbiol Immunol. 1994. PMID: 7935160 Clinical Trial.
-
Role of Herpes Simplex Envelope Glycoprotein B and Toll-Like Receptor 2 in Ocular Inflammation: An ex vivo Organotypic Rabbit Corneal Model.Viruses. 2019 Sep 4;11(9):819. doi: 10.3390/v11090819. Viruses. 2019. PMID: 31487910 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials